High-potency active ingredient specialist CDMO HAPILA GmbH (HAPILA) has extended its role within the German federally funded ATHANA alliance to regulatory consulting and advanced synthesis for nanoparticle drug delivery.
HAPILA’s regulatory role will include identification and synthesis of possible degeneration products and their structure as well as documentation to support planned pre-clinical trials . These will include efficacy and tolerability studies as the Alliance closes in on a developed drug prototype for pre-clinical studies, projected for early 2025.
HAPILA is also tackling the complex synthesis challenge of functionalizing a polymer backbone with dyes for drug targeting.
HAPILA extends role in ATHANA nanoparticle antifungal alliance to regulatory support
